Reproducibility of measures of leg muscle power, leg muscle strength, postural sway and mobility in people with Parkinson's disease.
This note indexes a cited or audit-added source. It may be an original study, review, guideline, form or methods reference. Treat the specific design and the evidence below as authoritative; a source note is not automatically a primary study.
DOI: 10.1016/j.gaitpost.2012.04.013
Bibliographic record from the original reports
Access labels embedded in these original reference strings are historical. Current access and exact checked components are stated separately below.
Paul SS, Canning CG, Sherrington C, et al. Reproducibility of measures of leg muscle power, leg muscle strength, postural sway and mobility in people with Parkinson's Disease. Gait & Posture. 2012. DOI 10.1016/j.gaitpost.2012.04.013
Paul SS, Canning CG, Sherrington C, Fung VSC. Reproducibility of measures of leg muscle power, leg muscle strength, postural sway and mobility in people with Parkinson’s disease. Gait & Posture. 2012;36(3):639–642. Original article
Paul SS, Canning CG, Sherrington C, Fung VS. Reproducibility of measures of leg muscle power, leg muscle strength, postural sway and mobility in people with Parkinson's disease. Gait Posture. 2012;36(3):639–42. DOI 10.1016/j.gaitpost.2012.04.013
Conditions: COND-PD Parkinson’s disease
Scoped audit evidence
These are source- and component-level audit summaries as of 3 October 2026. Access and comparison scope can differ by report; none certifies every result or the underlying raw data.
Parkinson’s disease — balance
- access status: scoped_publisher_HTML_transcription_and_original_supplement
Latest listed audit check, current for its stated components. Later recovery/refinement here supersedes earlier access limitations only where explicitly stated; it does not resolve unrelated source contradictions.
Revised balance P330–331/P334/P359/P380 matches scoped licensed publisher-HTML transcriptions:31,oneweek,sameassessor,matchedoptimalON,15dyskinesia/6disabling; Table2swayICC.04–.51SEM108–172. Table3posthocexclusionN25floorEC.80(.59–.91),SEM24 vs.29(-.07–.58),SEM136;foam.75 SEM34/40;floorEO.50(.14–.74). Table2balance-rangeN28 ICC.81(.63–.91)SEM17;coordinatedN31.50(.18–.72)SEM12 andN25.67(.38–.84)SEM5. Original binaryWordsupplementindependentlydecodedconfirmship-widthbarefoot,reported7mmfoam,floor/foamEOEC30sec,waistswaymeterpathmm;balance range3leans,andbestof2coordinated trials. Source locator: archived audit evidence archived source evidence; archived source evidence; archived source evidence evidence record Limit: Mainbodyis a prior AI transcription of licensedpublisherHTML, notoriginaljournalPDF orindependentlylive-reopenedHTML. Original supplement isbyte-verified source. Thisprovenancelevel retained.
Earlier audit check 1 (historical evidence record). Its access limitations are superseded wherever the latest check above explicitly closes them. Retained for the distinct components and provenance, not as a current access statement.
Balance P330–331/P334/P359/P380: originalabstractconfirms31participants,oneweekretest,ICC3,1sway.04–.51andpoorreliabilityespeciallydisablingdyskinesia. Source locator: Official indexed abstract archived source evidence Limit: FullMethods/supplement/Tables1–3 not independently recovered. AllpreciseprotocolandSEMsubgroupestimates remainunverified: sameexaminer/matchedON,15dyskinesia6disabling,7mmfoam/30s/hipwidth,SEM108–172,subgroupN25/ICC.80CI.59–.91SEM24/foam.75SEM34–40/floorEO.50CI.14–.74;APrangeICC.81CI.63–.91SEM17N28;coordinatedICC.50CI.18–.72SEM12 and.67CI.38–.84SEM5.
Limitations: Only scoped comparisons, not whole-paper certification.
Parkinson’s disease — balance1
- access status: scoped_publisher_HTML_transcription_and_original_supplement
Latest listed audit check, current for its stated components. Later recovery/refinement here supersedes earlier access limitations only where explicitly stated; it does not resolve unrelated source contradictions.
Revised balance P330–331/P334/P359/P380 matches scoped licensed publisher-HTML transcriptions:31,oneweek,sameassessor,matchedoptimalON,15dyskinesia/6disabling; Table2swayICC.04–.51SEM108–172. Table3posthocexclusionN25floorEC.80(.59–.91),SEM24 vs.29(-.07–.58),SEM136;foam.75 SEM34/40;floorEO.50(.14–.74). Table2balance-rangeN28 ICC.81(.63–.91)SEM17;coordinatedN31.50(.18–.72)SEM12 andN25.67(.38–.84)SEM5. Original binaryWordsupplementindependentlydecodedconfirmship-widthbarefoot,reported7mmfoam,floor/foamEOEC30sec,waistswaymeterpathmm;balance range3leans,andbestof2coordinated trials. Source locator: archived audit evidence archived source evidence; archived source evidence; archived source evidence evidence record Limit: Mainbodyis a prior AI transcription of licensedpublisherHTML, notoriginaljournalPDF orindependentlylive-reopenedHTML. Original supplement isbyte-verified source. Thisprovenancelevel retained.
Earlier audit check 1 (historical evidence record). Its access limitations are superseded wherever the latest check above explicitly closes them. Retained for the distinct components and provenance, not as a current access statement.
Balance P330–331/P334/P359/P380: originalabstractconfirms31participants,oneweekretest,ICC3,1sway.04–.51andpoorreliabilityespeciallydisablingdyskinesia. Source locator: Official indexed abstract archived source evidence Limit: FullMethods/supplement/Tables1–3 not independently recovered. AllpreciseprotocolandSEMsubgroupestimates remainunverified: sameexaminer/matchedON,15dyskinesia6disabling,7mmfoam/30s/hipwidth,SEM108–172,subgroupN25/ICC.80CI.59–.91SEM24/foam.75SEM34–40/floorEO.50CI.14–.74;APrangeICC.81CI.63–.91SEM17N28;coordinatedICC.50CI.18–.72SEM12 and.67CI.38–.84SEM5.
Limitations: Only scoped comparisons, not whole-paper certification.
Parkinson’s disease — strength
- access status: primary_main_sections_and_tables
STR-01-05
STR-01-01
STR-01-02
STR-01-03
STR-01-04
Limitations: Only current scoped checks; archived captures not authenticated against live originals.
Parkinson’s disease — transfer
- access status: archived_primary_html_transcription
30 STS observations among 31 participants; one-week matched optimal-ON retest. Baseline 9.67±1.79 s, retest 9.48±2.04 s, ICC(3,1)=.91 (.82–.96), SEM .6 s. Original supplement confirms 45-cm chair, folded arms, fastest of two maximal-speed trials; exact start/final event unspecified. Calculated MDC95=1.96√2×.6=1.663 s, approximately 1.7 s.
Limitations: Only the enumerated transfer-relevant components were adjudicated. Source availability does not imply every statement, supplement, figure or raw datum was checked.
Parkinson’s disease strength
- current access: primary_main_sections_and_tables
- primary version: Labelled publisher-HTML transcription: complete Methods, Results, Tables1–3; companion Discussion/references and original .doc supplement
Parkinson’s disease strength component — Complete reported Keiser protocol, side labels and omissions
Methods 2.1–2.2 gives 31 community-dwelling independently ambulant participants, one assessor, one-week retest at the same optimal ON time; seated unilateral leg press before standing hip abduction; randomized side order preserved; peak power across six relative loads 30–80% 1 RM. First/second labels refer to the randomized test order. The separate supplement adds balance and mobility methods, not the missing strength-machine range, stabilization, load order, effort counts, rest, velocity sensing or power algorithm. Standing balance demand is the report’s biomechanical inference.
Source locator: https://doi.org/10.1016/j.gaitpost.2012.04.013; Library original archived audit evidence Methods 2.1–2.3 and original archived source evidence supplement
Limitations: AI-assisted comparison with archived licensed capture; transcription accuracy was not independently verified against the live publisher original.
Parkinson’s disease strength component — All eight strength/power ICCs, intervals, SEMs and baseline denominators in report Table 4
Primary Table 2: leg power first 466.9 W, ICC .96 (.91–.98), SEM 35; second 485.1, .95 (.90–.98), 36. Hip power first 105.5 W, .85 (.71–.92), 18.5; second 104.1, .93 (.87–.97), 12.5. Leg strength first 864.5 N, .96 (.92–.98), 50; second 881.4, .97 (.94–.99), 43. Hip strength first 58.3 Nm, .93 (.86–.97), 6; second 59.7, .96 (.92–.98), 5. All report ICC/CI/SEM cells match. Recalculated MDC and percentages also match the report at displayed precision.
Source locator: https://doi.org/10.1016/j.gaitpost.2012.04.013; Library original archived audit evidence Table 2; audit evidence record
Limitations: AI-assisted comparison with archived licensed capture; transcription accuracy was not independently verified against the live publisher original.
Parkinson’s disease strength component — Retest mean shifts and dyskinesia subgroup
Table 2 hip-strength means 58.3→62.0 and 59.7→63.5 Nm. No paired significance test for those shifts appears in recovered Methods/Results. Table 1 has 15 dyskinesia, 6 disabling dyskinesia and 16 motor fluctuations. Table 3 muscle ICC/SEM values change modestly after removing six disabling cases, unlike sway: floor eyes-open ICC.04→.50, SEM 172→30 and eyes-closed .29→.80, 136→24. This supports the report’s limited comparison, without proving no individual contamination.
Source locator: https://doi.org/10.1016/j.gaitpost.2012.04.013; Library original archived audit evidence Tables 1–3; Discussion companion
Limitations: AI-assisted comparison with archived licensed capture; transcription accuracy was not independently verified against the live publisher original.
Linked audit findings
Reports citing this source
- Standing balance assessment and prognosis in Parkinson’s disease · reference 90 · original reference
- Standing balance assessment and prognosis in Parkinson’s disease · reference 29 · original reference
- Sit to stand and functional transfer assessment and prognosis in Parkinson’s disease · reference 4 · original reference
- Strength muscle power and rapid force production assessment in Parkinson’s disease · reference 1 · original reference
Update record
- 2026-10-03: Created from the supplied reports and final scoped audit. New evidence should be appended with source version, access date, exact locator and affected report links.
Updating the wiki · Evidence and status guide